We are live on
!
Find out more
SM
Sabby Management Portfolio holdings
AUM
$111M
1-Year Est. Return
74.4%
This Fund
S&P 500
This Quarter
Est. Return
+0.11%
1 Year Est. Return
-74.4%
3 Year Est. Return
-95.55%
5 Year Est. Return
-99.44%
10 Year Est. Return
-99.5%
AUM
$709M
AUM Growth
+$195M
(+38%)
Cap. Flow
+$27.5M
Cap. Flow
% of AUM
3.88%
Top 10 Holdings %
Top 10 Hldgs %
69.09%
Holding
206
New
48
Increased
50
Reduced
50
Closed
43
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Aterian
ATER
|
+$8.44M |
| 2 |
Cocrystal Pharma
COCP
|
+$7.74M |
| 3 |
Recon Technology
RCON
|
+$7.51M |
| 4 |
LNAI
Lunai Bioworks
LNAI
|
+$5.46M |
| 5 |
KRBP
Kiromic BioPharma, Inc. Common Stock
KRBP
|
+$4.18M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Vivani Medical
VANI
|
+$4.81M |
| 2 |
PENN Entertainment
PENN
|
+$4.24M |
| 3 |
VirTra
VTSI
|
+$3.45M |
| 4 |
ASXC
Asensus Surgical, Inc.
ASXC
|
+$3.42M |
| 5 |
RVPH
REVIVA PHARMA HLDGS INC
RVPH
|
+$2.4M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 81.19% |
| 2 | Healthcare | 12.07% |
| 3 | Consumer Discretionary | 1.47% |
| 4 | Financials | 1.38% |
| 5 | Technology | 1.07% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
51
Zevra Therapeutics
ZVRA
$713M
| $2.21M | 0.31% |
+172,163
| New | +$1.85M |
|
|
STAB
52
DELISTED
Statera Biopharma, Inc. Common Stock
STAB
| $2.19M | 0.31% |
400,080
-78,861
| -16% | -$425K |
|
53
MMTec
MTC
$472M
| $2.09M | 0.29% |
12,543
-4,343
| -26% | -$624K |
|
|
IMG
54
DELISTED
CIMG Inc
IMG
| $2.08M | 0.29% |
943
-436
| -32% | -$979K |
|
|
NMRD
55
PUT
DELISTED
Nemaura Medical, Inc. Common Stock
NMRD
| $2.08M | 0.29% |
2,005
+1,504
| +300% | +$14.4K |
|
|
NMTR
56
PUT
DELISTED
9 Meters Biopharma
NMTR
| $1.99M | 0.28% |
906
-404
| -31% | -$9.92K |
|
57
PUT
Oramed Pharmaceuticals
ORMP
$194M
| $1.9M | 0.27% |
1,418
-268
| -16% | -$3.06K |
|
|
TCDA
58
DELISTED
Tricida, Inc. Common Stock
TCDA
| $1.89M | 0.27% |
436,500
+81,745
| +23% | +$390K |
|
|
ADOM
59
DELISTED
ADOMANI Inc
ADOM
| $1.82M | 0.26% |
+6,166,711
| New | +$1.82M |
|
|
BCLI
60
PUT
DELISTED
BRAINSTORM CELL THERAPUTC
BCLI
| $1.79M | 0.25% |
314
+19
| +6% | +$1.01K |
|
|
ASXC
61
PUT
DELISTED
Asensus Surgical, Inc.
ASXC
| $1.77M | 0.25% |
5,594
-1,365
| -20% | -$3.41K |
|
|
AFIB
62
DELISTED
Acutus Medical Inc
AFIB
| $1.75M | 0.25% |
103,100
-29,422
| -22% | -$430K |
|
63
PUT
XWELL
XWEL
$8.29M
| $1.71M | 0.24% |
554
-94
| -15% | -$2.68K |
|
64
PUT
Lisata Therapeutics
LSTA
$14.7M
| $1.68M | 0.24% |
694
-103
| -13% | -$2.44K |
|
|
CVM.WS
65
PUT
DELISTED
Cel-Sci Corp Series S
CVM.WS
| $1.66M | 0.23% |
1,916
+468
| +32% | +$406K |
|
|
WIMI
66
PUT
WiMi Hologram Cloud
WIMI
$18.9M
| $1.61M | 0.23% |
294
+110
| +60% | +$6.18K |
|
67
PUT
Ocean Power Technologies
OPTT
$24.6M
| $1.5M | 0.21% |
139
+1
| +0.7% | +$74 |
|
|
AMRN
68
PUT
Amarin Corp
AMRN
$291M
| $1.48M | 0.21% |
169
+153
| +956% | +$15K |
|
|
AMRN
69
Amarin Corp
AMRN
$291M
| $1.43M | 0.2% |
16,349
+7,892
| +93% | +$775K |
|
|
ADTX
70
PUT
DELISTED
ADITXT INC
ADTX
| – | – |
0
| – | – |
|
|
TRIL
71
DELISTED
Trillium Therapeutics Inc.
TRIL
| $1.39M | 0.2% |
143,496
-56,073
| -28% | -$528K |
|
72
Biogen
BIIB
$32.1B
| $1.39M | 0.2% |
+4,000
| New | +$1.21M |
|
|
INFI
73
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
| $1.32M | 0.19% |
441,473
-88,527
| -17% | -$280K |
|
74
CEL-SCI Corp
CVM
$26.7M
| $1.26M | 0.18% |
+4,843
| New | +$3M |
|
75
Inhibikase Therapeutics
IKT
$327M
| $1.18M | 0.17% |
+70,200
| New | +$2.07M |
|
Similar funds
IWA
BFA
WPWM
BCM
ZS
KC
FI
CIM
Sabby Management's Q2 2021 Portfolio in Review
As of Q2 2021, Sabby Management held 206 positions worth $709M, up 38% from $514M the previous quarter. Its ten largest holdings account for 69% of the portfolio.
Sabby Management deployed $27.5M of net new capital in Q2 2021, opening 48 new positions and adding to 50 existing holdings. Its largest new stake was Aterian: 36,083 shares worth $6.33M.
By sector, the portfolio is most concentrated in Miscellaneous at 81% of assets, up from 76% a quarter earlier, followed by Healthcare and Consumer Discretionary.
On the sell side, the largest reduction was Vivani Medical, an estimated $4.81M trimmed.
- Sabby Management's largest Q2 2021 buy was Aterian: 36,083 shares worth $6.33M.
- Sabby Management added most to Vincerx Pharma, Inc. Common Stock in Q2 2021, an estimated $2.87M increase.
- Sabby Management's biggest Q2 2021 reduction was Vivani Medical, cutting an estimated $4.81M.
- Sabby Management fully exited PENN Entertainment in Q2 2021, selling an estimated $4.24M.
- Sabby Management's ten largest holdings make up 69% of its $709M portfolio in Q2 2021.
- Sabby Management opened 48 new positions and closed 43 in Q2 2021.
- Sabby Management's portfolio value rose 38% quarter-over-quarter to $709M.
Based on Sabby Management's 13F filing for Q2 2021, filed 16 Aug 2021.